EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Cancer-Therapy-Related Cardiac Dysfunction: Latest Advances in Prevention and Treatment

Carla Contaldi, Carmine D'Aniello, Domenico Panico, Andrea Zito, Paolo Calabrò iD, Emilio Di Lorenzo, Paolo Golino iD, Vincenzo Montesarchio

Life · 15.03.2025 · 15 (3) · 471

DOI: 10.3390/life15030471 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Life, online erschienen am 15.03.2025. Verfasst von Carla Contaldi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, AORN dei Colli-Monaldi Hospital, 80131 Naples, Italy. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 204 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The increasing efficacy of cancer therapies has significantly improved survival rates, but it has also highlighted the prevalence of cancer-therapy-related cardiac dysfunction (CTRCD). This review provides a comprehensive overview of the identification, monitoring, and management of CTRCD, a condition resulting from several treatments, such as anthracyclines, HER2-targeted therapies, target therapies, and radiotherapy. The paper includes a discussion of the mechanisms of CTRCD associated with various cancer treatments. Early detection through serum biomarkers and advanced imaging techniques is crucial for effective monitoring and risk stratification. Preventive strategies include pharmacological interventions such as ACE inhibitors/angiotensin receptor blockers, beta-blockers, and statins. Additionally, novel agents like sacubitril/valsartan, sodium-glucose co-transporter type 2 inhibitors, and vericiguat show promise in managing left ventricular dysfunction. Lifestyle modifications, including structured exercise programs and optimized nutritional strategies, further contribute to cardioprotection. The latest treatments for both asymptomatic and symptomatic CTRCD across its various stages are also discussed. Emerging technologies, including genomics, artificial intelligence, novel biomarkers, and gene therapy, are paving the way for personalized approaches to CTRCD prevention and treatment. These advancements hold great promise for improving long-term outcomes in cancer patients by minimizing cardiovascular complications.

Schlagwörter

Stichwörter der Autor:innen

biomarkerscancer-therapy-related cardiac dysfunction (CTRCD)emerging technologiesimaging techniquespharmacological interventions

Autor:innen und Institutionen

  • Department of Cardiology, AORN dei Colli-Monaldi Hospital, 80131 Naples, Italy.
  • Division of Medical Oncology, AORN dei Colli-Monaldi Hospital, 80131 Naples, Italy.
  • Department of Translational Medical Sciences, University of Campania "Luigi Vanvitelli", 80131 Naples, Italy.

ORCID-Profile: Paolo Calabrò, Paolo Golino

Zitieren

APA

Contaldi, C., D'Aniello, C., Panico, D., Zito, A., Calabrò, P., Di Lorenzo, E., Golino, P., & Montesarchio, V. (2025). Cancer-Therapy-Related Cardiac Dysfunction: Latest Advances in Prevention and Treatment. Life, 15(3), 471. https://doi.org/10.3390/life15030471

Vancouver

Contaldi C, D'Aniello C, Panico D, Zito A, Calabrò P, Di Lorenzo E, et al. Cancer-Therapy-Related Cardiac Dysfunction: Latest Advances in Prevention and Treatment. Life. 2025;15(3):471. doi:10.3390/life15030471

BibTeX
@article{Contaldi2025,
  author = {Contaldi, Carla and D'Aniello, Carmine and Panico, Domenico and Zito, Andrea and Calabrò, Paolo and Di Lorenzo, Emilio and Golino, Paolo and Montesarchio, Vincenzo},
  title = {Cancer-Therapy-Related Cardiac Dysfunction: Latest Advances in Prevention and Treatment},
  journal = {Life},
  year = {2025},
  volume = {15},
  number = {3},
  pages = {471},
  doi = {10.3390/life15030471}
}
Kostenlos starten →